CJC-1295 With DAC vs Without DAC (Mod GRF 1-29), Sermorelin, Tesamorelin and Ipamorelin: A Research Review of the GRF(1-29) Sequence Lineage, DPP-IV Cleavage, the Four Amino-Acid Substitutions, Albumin Cys34 Drug Affinity Complex Chemistry and the Catalogue Vocabulary Behind "cjc-1295 without dac", "cjc-1295 w/dac" and "what does no dac mean in peptides" Labels

Peptide Insider Editorial Research Desk · 2026-09-25 · Mechanism & Pathways · Research reference only

Search logs for the growth-hormone-releasing-hormone (GHRH) analogue family are dominated by a single lexical fork: cjc-1295 without dac versus cjc-1295 w/dac, with the question what does no dac mean in peptides appearing alongside dual listings such as cjc-no dac / ipamorelin and tesamorelin & ipamorelin blend. Behind that fork sits one of the clearest structure-to-pharmacokinetics stories in peptide chemistry: a 29-residue fragment of a 44-residue hypothalamic hormone, a dipeptidyl-peptidase cleavage site that limits its plasma survival to minutes, four amino-acid substitutions that close that site, and a maleimide linker that covalently parks the peptide on serum albumin. This review traces that lineage from sermorelin to Mod GRF 1-29, CJC-1295 and tesamorelin, records the selective ghrelin-receptor agonist ipamorelin that is routinely co-listed with them, and then classifies the catalogue vocabulary into research-scope terms and out-of-scope (dosage, therapeutic, price) terms.

1. The parent sequence: from GHRH(1-44) to GRF(1-29)

Human GHRH was isolated in 1982 from pancreatic islet tumours associated with acromegaly, and characterised as a 44-residue amidated peptide (with 40- and 37-residue forms also present) [1] [2]. Structure–activity studies established that the N-terminal 29 residues carry essentially all receptor-binding and GH-releasing activity: analogues and fragments were compared for pituitary receptor binding and cAMP/GH release, and truncation beyond residue 29 sharply reduced potency while residues 30–44 were dispensable [3]. Systematic analogue series confirmed that residues Tyr1, Ala2, Asp3, and the amphipathic helix spanning roughly residues 6–27 are the principal pharmacophores, with Lys12, Lys21, Leu22 and Leu23 contributing to receptor affinity [4].

That 29-residue amide, GRF(1-29)NH2, is sermorelin (International Nonproprietary Name; the “-relin” stem denotes a releasing-factor analogue, pronounced ser-mo-REL-in). It was formulated as the acetate salt and reviewed as a diagnostic and paediatric agent in the 1990s [8]; a later commentary discussed it in the context of adult somatotropic insufficiency [9]. In research catalogues it appears as sermorelin research peptide or sermorelin powder, and in misspelled forms such as sermorelon and semorellin. The receptor it targets, GHRHR, is a class B G-protein-coupled receptor cloned from rat and human pituitary in 1992–1993; it signals through Gαs and adenylyl cyclase to raise somatotroph cAMP [24] [25].

2. Why GRF(1-29) is short-lived: the Ala2–Asp3 cleavage site

Frohman and colleagues showed in 1986 that GHRH incubated in human plasma is rapidly converted to a biologically inactive product cleaved at the NH2 terminus, and that the same conversion occurs in vivo [5]. The follow-up study identified the responsible enzyme as dipeptidyl peptidase IV (DPP-IV, CD26), which removes the N-terminal Tyr1-Ala2 dipeptide to yield GHRH(3-44), with a secondary trypsin-like cleavage contributing at basic residues [6]. Parallel work on rat GRF(1-29)NH2 in serum and liver confirmed rapid N-terminal and internal proteolysis [7]. Because Tyr1 and Ala2 are pharmacophores, the DPP-IV product has negligible activity; the plasma half-life of native GRF(1-29) in the human study was on the order of minutes [11].

This is the mechanistic reason every longer-acting analogue in the family modifies the N-terminus. Two design routes appear in the literature: (a) substitute residue 2 with a D-amino acid so DPP-IV cannot recognise the Xaa-Ala/Pro motif, and (b) cap the N-terminus with an acyl group. Route (a) produced Mod GRF 1-29 and CJC-1295; route (b) produced tesamorelin.

3. Mod GRF 1-29 (“CJC-1295 without DAC”): the four substitutions

The peptide core of CJC-1295 is GRF(1-29)NH2 carrying four substitutions: D-Ala2, Gln8, Ala15 and Leu27 [10]. Each has a stability rationale. D-Ala2 blocks DPP-IV cleavage. Gln8 replaces Asn8, removing a deamidation-prone asparagine (Asn-Ser and Asn-Gly motifs deamidate via succinimide intermediates under storage) [27]. Ala15 replaces Gly15, increasing helix propensity and reported receptor affinity in analogue series [3] [4]. Leu27 replaces Met27, removing the sulfur-containing residue most susceptible to oxidation [27]. This tetrasubstituted peptide is what catalogues call cjc-1295 without dac, cjc-1295 w/o dac, cjc no dac peptide or Mod GRF 1-29; the query cjc-1295 no dac amino acid substitutions resolves to exactly this list. Strictly, the developer’s designation CJC-1295 refers to the albumin-binding conjugate, so “CJC-1295 without DAC” is a catalogue back-formation rather than a literature name [10].

4. The Drug Affinity Complex: covalent albumin binding at Cys34

Human serum albumin (UniProt P02768) carries 35 cysteines, 34 of which are disulfide-paired; Cys34 is the single free thiol and is the most reactive nucleophile in plasma. Maleimide groups react with it selectively to form a stable thioether, a strategy reviewed extensively as an approach to half-life extension because albumin itself circulates for about 19 days through FcRn-mediated recycling [15] [16]. Jetté and colleagues appended a maleimidopropionic-acid (MPA) group to an added Lys30 on the tetrasubstituted GRF(1-29) core; the resulting compound (CJC-1295) formed bioconjugates with rat and human albumin in vitro and, after administration in rats, remained detectable as an albumin conjugate that continued to activate the pituitary GRF receptor and elevate GH and IGF-1 for days rather than minutes [10].

The human pharmacology was reported by Teichman et al. in a randomised, placebo-controlled study of healthy adults: single administrations of CJC-1295 produced dose-dependent increases in mean plasma GH (approximately 2- to 10-fold) for six days or more and in IGF-1 (approximately 1.5- to 3-fold) for nine to eleven days, with an estimated elimination half-life of 5.8–8.1 days; after multiple administrations, IGF-1 remained elevated for up to 28 days [11]. Ionescu and Frohman then showed that the physiological pulsatility of GH secretion was preserved during continuous GHRHR stimulation by CJC-1295, with pulse amplitude rather than pulse frequency increased [12]. In GHRH-knockout mice, once-daily CJC-1295 restored body-weight gain and normalised pituitary GH content [13], and serum proteomic profiling in adult subjects documented the downstream protein-level footprint of GH/IGF-1 axis activation [14]. In catalogue orthography this compound is cjc-1295 w/dac, cjc-1295 w dac, cjc 1295 dac peptide, cjc1295dac or cjc dac 1295; the questions what is dac in cjc 1295, what is cjc 1295 dac and cjc and dac all resolve to the MPA–albumin chemistry described here.

5. Tesamorelin: N-terminal acylation of the full 44-residue sequence

Tesamorelin (TH9507; DrugBank DB06285) takes the alternative design route: it is the complete human GHRH(1-44)NH2 sequence with a trans-3-hexenoyl group on the N-terminal tyrosine. Non-clinical pharmacology showed the acyl cap conferred resistance to DPP-IV cleavage and a longer functional duration than native GHRH while retaining full GHRHR agonism and native-like GH pulsatility [17]. Its clinical literature is unusually large for this family: a phase 3 randomised trial published in the New England Journal of Medicine in 2007 [18], a pooled analysis of two phase 3 trials in 2010 [19], and a 2014 randomised trial in JAMA measuring visceral and hepatic fat by imaging [20]. Those reports describe the compound’s effects in a specific patient population under medical supervision; they are cited here as literature record and for mechanistic comparison only, not as guidance for any use of research-grade material. The catalogue tokens ipamorelin tesamorelin, tesa ipamorelin, tesamorelin & ipamorelin blend, tesamorelin + ipamorelin blend and tesamorelin cjc1295 ipamorelin pair it with GHS-R agonists, as discussed next.

6. Ipamorelin: why the second receptor is co-listed

GH release from the somatotroph is governed by two stimulatory receptors and one inhibitory input: GHRHR (agonised by all four analogues above), the growth hormone secretagogue receptor GHS-R1a (UniProt Q92847; the ghrelin receptor), and somatostatin receptors. Muller, Locatelli and Cocchi’s comprehensive Physiological Reviews article describes how GHRHR and GHS-R agonists act on distinct second-messenger systems (cAMP versus phospholipase C/Ca2+) and interact synergistically at the somatotroph and hypothalamus [23]. Bowers’ review of the growth hormone-releasing peptides traces the GHRP lineage from met-enkephalin-derived hexapeptides to the identification of GHS-R [22]. Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) was characterised by Raun et al. in 1998 as the first GHS with selectivity for GH release over ACTH and cortisol in rat and swine models, with in-vivo potency similar to GHRP-6 [21]. A 2020 narrative review in Translational Andrology and Urology summarises the secretagogue class, including the CJC-1295/ipamorelin pairing, from a clinical-literature standpoint [26]. This dual-receptor logic is why catalogue listings such as cjc 1295 no dac / ipamorelin, cjc 1295 no dac + ipamorelin, ipamorelin / cjc-1295 no dac, ipamorelin cjc-1295 without dac, cjc ipamorelin no dac, cjc 1295 dac ipamorelin, cjc-1295 & ipamorelin blend, ipamorelin + cjc-1295, cjc-1295/ipamorelin peptides, cjc-1295/ipamorelin peptide, peptides cjc 1295 ipamorelin, ipa/cjc-1295, cjc1295 no dac ipamorelin and the misspelling cj1295 ipamorelin exist: they name a GHRHR agonist and a GHS-R1a agonist in one line. Triple listings (sermorelin ipamorelin and cjc 1295, sermorelin ipamorelin cjc 1295, tesamorelin & mod grf & ipamorelin blend) combine two GHRHR agonists with one GHS-R agonist and have no dedicated literature.

7. Evidence table

Compound / modification	Research model	Signal vector	Key observation	Ref
GHRH(1-44)NH2, native	Human pancreatic islet tumour isolation; rat pituitary bioassay	GH release, sequence	44-residue amide identified; 40/37-residue forms co-isolated	[1] [2]
GRF(1-29)NH2 (sermorelin)	Rat pituitary membranes; analogue/fragment series	Receptor binding, cAMP, GH	Residues 1-29 retain full activity; C-terminal 30-44 dispensable	[3] [4]
GHRH in plasma	Human plasma in vitro; human in vivo	HPLC/RIA of fragments	DPP-IV cleaves Tyr1-Ala2 within minutes; product inactive	[5] [6]
rGRF(1-29)NH2	Rat serum and liver	HPLC catabolite mapping	N-terminal and internal proteolysis	[7]
Mod GRF 1-29 core (D-Ala2, Gln8, Ala15, Leu27)	Design rationale; rat pituitary cells	cAMP, GH	Substitutions confer DPP-IV resistance and chemical stability	[10] [27]
CJC-1295 (Lys30-MPA conjugate)	Rat in vivo; albumin bioconjugation in vitro	Albumin-conjugate detection; GH, IGF-1	Covalent albumin binding; multi-day GH/IGF-1 elevation	[10]
CJC-1295	Healthy adults, randomised placebo-controlled	Plasma GH, IGF-1, PK	t1/2 5.8-8.1 d; IGF-1 elevated 9-11 d after single administration	[11]
CJC-1295	Healthy adults, frequent sampling	GH pulse analysis	Pulsatility preserved; amplitude increased	[12]
CJC-1295	GHRH-knockout mouse	Body weight, pituitary GH	Once-daily administration normalised growth	[13]
CJC-1295	Adult subjects, serum proteomics	2-D gel protein profile	GH/IGF-1-dependent serum protein changes	[14]
Albumin Cys34 maleimide chemistry	Review	Half-life extension platform	FcRn recycling gives ~19 d albumin half-life	[15] [16]
Tesamorelin (trans-3-hexenoyl-GHRH(1-44))	Non-clinical pharmacology/toxicology	GH, IGF-1; stability	DPP-IV resistance with native-like pulsatility	[17]
Tesamorelin	Phase 3 RCTs and pooled analysis (patient population)	CT-measured adipose depots, IGF-1	Clinical literature record; outside RUO scope	[18] [19] [20]
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2)	Rat pituitary cells; rat and swine in vivo	GH, ACTH, cortisol	GH-selective GHS; no ACTH/cortisol rise	[21]
GHRHR / GHS-R axis	Reviews; receptor cloning	cAMP vs PLC/Ca2+	Distinct receptors; synergistic somatotroph activation	[22] [23] [24] [25]

8. Catalogue-vocabulary crosswalk and RUO scope status

The following table records verbatim query strings observed in research-catalogue search logs, maps each to its chemical referent, and states its research-use-only scope status. Strings classified as Declined carry dosage, therapeutic, tolerability, consumer dosage-form or price semantics and receive no substantive answer on this site; they are listed solely so the reader can see how the nomenclature is used and why those framings fall outside a research review. Note the fill-mass strings (for example ipamorelin 10 mg) describe lyophilised net peptide per vial and are not administration quantities.

Verbatim query string	Chemical referent / classification	RUO scope status
cjc-1295 without dac	Mod GRF 1-29 (tetrasubstituted GRF(1-29)NH2 without the MPA linker)	Recorded as nomenclature
cjc-1295 w/dac	CJC-1295 proper: Mod GRF 1-29 + Lys30-MPA Drug Affinity Complex	Recorded as nomenclature
cjc-1295 w dac	Same as above; whitespace variant	Recorded as nomenclature
cjc-1295 w/o dac	Mod GRF 1-29; abbreviation variant	Recorded as nomenclature
cjc-1295 no-dac	Mod GRF 1-29; hyphen variant	Recorded as nomenclature
cjc-no dac	Mod GRF 1-29; truncated variant	Recorded as nomenclature
cjc no dac peptide	Mod GRF 1-29	Recorded as nomenclature
no dac peptide	Any GRF(1-29) analogue lacking the albumin-binding linker	Recorded as terminology
what does no dac mean in peptides	Absence of the maleimidopropionic-acid albumin-binding linker	Recorded as terminology (question form)
what is dac in cjc 1295	Drug Affinity Complex: Lys30-MPA that binds albumin Cys34	Recorded as terminology (question form)
what is cjc 1295 dac	CJC-1295 with the albumin-binding linker	Recorded as nomenclature (question form)
what is cjc-1295 with dac	Same referent	Recorded as nomenclature (question form)
what is cjc 1295 no dac	Mod GRF 1-29	Recorded as nomenclature (question form)
what is cjc 1295 peptide	Family-level query; either variant	Recorded as nomenclature (question form)
cjc-1295 peptide what is it	Family-level query	Recorded as nomenclature (question form)
cjc-1295 no dac amino acid substitutions	D-Ala2, Gln8, Ala15, Leu27	Recorded as terminology
cjc 1295 dac peptide	CJC-1295 with DAC	Recorded as nomenclature
cjc-1295 dac peptide	CJC-1295 with DAC; hyphen variant	Recorded as nomenclature
cjc 1295 with dac peptide	CJC-1295 with DAC	Recorded as nomenclature
cjc dac 1295	Token re-ordering	Recorded as nomenclature
cjc and dac	Family + linker tokens	Recorded as nomenclature
cjc1295dac	Whitespace collapse	Recorded as orthographic variant
cjc1295 no dac ipamorelin	Mod GRF 1-29 + ipamorelin dual-agonist listing	Recorded as nomenclature
cj1295 ipamorelin	Digit-drop misspelling of CJC-1295 + ipamorelin	Recorded as orthographic variant
peptide cjc1295	Whitespace collapse	Recorded as orthographic variant
cjc 5	Prefix truncation (ambiguous)	Recorded as orthographic variant
cjc-no dac / ipamorelin	Dual-agonist listing (GHRH-R + GHS-R)	Recorded as nomenclature
cjc 1295 no dac / ipamorelin	Dual-agonist listing	Recorded as nomenclature
cjc 1295 no dac + ipamorelin	Dual-agonist listing	Recorded as nomenclature
ipamorelin / cjc-1295 no dac	Dual-agonist listing, reversed order	Recorded as nomenclature
ipamorelin cjc-1295 without dac	Dual-agonist listing	Recorded as nomenclature
cjc ipamorelin no dac	Dual-agonist listing	Recorded as nomenclature
cjc 1295 dac ipamorelin	CJC-1295 with DAC + ipamorelin listing	Recorded as nomenclature
cjc-1295 & ipamorelin blend	Dual-agonist listing (linker unspecified)	Recorded as nomenclature
ipamorelin + cjc-1295	Dual-agonist listing	Recorded as nomenclature
cjc-1295/ipamorelin peptides	Dual-agonist listing	Recorded as nomenclature
cjc-1295/ipamorelin peptide	Dual-agonist listing	Recorded as nomenclature
peptides cjc 1295 ipamorelin	Dual-agonist listing	Recorded as nomenclature
ipa/cjc-1295	Abbreviated dual-agonist listing (IPA = ipamorelin)	Recorded as nomenclature
cjc 1295 ipamorelin half life	Pharmacokinetic query; see Table 1 (Teichman 2006; Raun 1998)	Recorded as terminology (question form)
sermorelin ipamorelin and cjc 1295	Triple listing across GHRH-R and GHS-R agonists	Recorded as nomenclature
sermorelin ipamorelin cjc 1295	Triple listing	Recorded as nomenclature
tesamorelin cjc1295 ipamorelin	Triple listing	Recorded as nomenclature
tesamorelin & mod grf & ipamorelin blend	Triple listing naming Mod GRF 1-29 explicitly	Recorded as nomenclature
sermorelon	Vowel substitution misspelling of sermorelin	Recorded as orthographic variant
semorellin	Consonant drop/double misspelling of sermorelin	Recorded as orthographic variant
sermorelin.	Trailing punctuation variant	Recorded as orthographic variant
sermorelin research peptide	GRF(1-29)NH2 acetate	Recorded as nomenclature
sermorelin powder	Lyophilised presentation descriptor	Recorded as catalogue terminology
how to pronounce sermorelin	ser-mo-REL-in (INN stem -relin = releasing-factor analogue)	Recorded as terminology (question form)
sermorelin pronounce	Same referent	Recorded as terminology
sermorelin peptide what does it do	GHRH-R agonist; see Mechanism section	Recorded as terminology (question form)
what does ipamorelin peptide do	GHS-R1a agonist; see Mechanism section	Recorded as terminology (question form)
ipamorelin tesamorelin	Dual-agonist listing (GHRH-R + GHS-R)	Recorded as nomenclature
tesa ipamorelin	Abbreviated dual listing (tesa = tesamorelin)	Recorded as nomenclature
tesamorelin & ipamorelin blend	Dual-agonist listing	Recorded as nomenclature
tesamorelin + ipamorelin blend	Dual-agonist listing	Recorded as nomenclature
ipamorelin 10 mg	Catalogue fill-mass descriptor (lyophilised net peptide)	Recorded as catalogue terminology
ipamorelin 2mg	Catalogue fill-mass descriptor	Recorded as catalogue terminology
cjc-1295 dac 10mg	Catalogue fill-mass descriptor	Recorded as catalogue terminology
tesamorelin peptide 10 mg	Catalogue fill-mass descriptor	Recorded as catalogue terminology
tesamorelin/ipamorelin dosage	Dosage query	Declined - dosage
tesamorelin + ipamorelin blend dosage per day	Dosage query	Declined - dosage
sermorelin peptide dosage chart	Dosage query	Declined - dosage
cjc-1295 with dac dosing protocol	Dosage/protocol query	Declined - dosage
tesamorelin cjc1295 ipamorelin 12mg blend dose	Dosage query	Declined - dosage
how much bacteriostatic water to mix with 5mg of cjc-1295	Preparation-protocol query	Declined - protocol
sermorelin hair growth	Outcome/benefit claim	Declined - health claim
cjc 1295 with dac benefits	Outcome/benefit claim	Declined - health claim
cjc-1295 + ipamorelin muscle growth	Outcome/benefit claim	Declined - health claim
cjc-1295 ipamorelin body recomposition	Outcome/benefit claim	Declined - health claim
cjc 1295 ipamorelin peptide therapy	Therapeutic-use framing	Declined - human use
side effects of cjc 1295 dac	Human tolerability query	Declined - human use
cjc 1295 ipamorelin hot flush	Human tolerability query	Declined - human use
sermorelin peptide supplement	Supplement framing	Declined - human use
sermorelin otc	Over-the-counter framing	Declined - human use
sermorelin mints	Consumer dosage-form framing	Declined - human use
tesamorelin tablets for sale	Consumer dosage-form + commerce	Declined - promo
compounded tesamorelin	Pharmacy-compounding framing	Declined - human use
how much does tesamorelin cost	Price query	Declined - promo/price
tesamorelin prices	Price query	Declined - promo/price
why is tesamorelin so expensive	Price query	Declined - promo/price

9. Handling notes for the lyophilised analogues

All four GHRHR agonists and ipamorelin are supplied to laboratories as lyophilised powders. The stability considerations reviewed by Manning et al. apply directly: the native Asn8 and Met27 of sermorelin are deamidation- and oxidation-prone, which is precisely why Mod GRF 1-29 substitutes them; tesamorelin retains Asn8 and Met27 and the additional Met and Asn residues of the 30-44 tail; and the maleimide of CJC-1295 is itself a reactive electrophile that will hydrolyse or react with thiol-containing excipients in solution, so the conjugate is only meaningful when formed in the presence of albumin [27]. Certificates of analysis should therefore report RP-HPLC purity and mass-spectrometric identity for the intact sequence, and for CJC-1295 confirm that the MPA group is present. Reconstitution-solvent chemistry is covered in our reconstitution-solvent review; the individual compound reviews for CJC-1295, tesamorelin and ipamorelin, the somatotropic-axis nomenclature review, the MK-677 non-peptide secretagogue review and the receptor-family index provide the wider context.

10. Frequently asked research questions

What does no dac mean in peptides?

“No DAC” means the GRF(1-29) analogue lacks the Drug Affinity Complex: the maleimidopropionic-acid group on Lys30 that covalently binds albumin Cys34. The peptide is otherwise identical to the CJC-1295 core (D-Ala2, Gln8, Ala15, Leu27) and is properly called Mod GRF 1-29 [10].

What is cjc 1295 dac and how does it differ from sermorelin?

CJC-1295 with DAC is a tetrasubstituted GRF(1-29)NH2 carrying an albumin-binding linker; sermorelin is the unmodified native GRF(1-29)NH2. In plasma the native peptide is cleaved by DPP-IV within minutes, whereas the albumin-bound conjugate showed an elimination half-life of 5.8–8.1 days in the published human study [5] [6] [11].

What are the cjc-1295 no dac amino acid substitutions?

D-Ala2 (blocks DPP-IV), Gln8 (removes a deamidation-prone Asn), Ala15 (increases helicity and affinity) and Leu27 (removes an oxidation-prone Met), relative to native GRF(1-29) [10] [27].

What is the cjc 1295 ipamorelin half life relationship?

They are separate molecules with separate kinetics. Albumin-bound CJC-1295 has a multi-day half-life [11]; ipamorelin, a pentapeptide without a half-life-extension moiety, showed a short duration of GH release in the original rat and swine characterisation [21]. Co-listing does not create a shared half-life.

What does ipamorelin peptide do at the receptor level, and why is it paired with GHRH analogues?

Ipamorelin is a GHS-R1a agonist that stimulates GH release without raising ACTH or cortisol in the rat and swine models studied [21]. GHS-R1a and GHRHR use different second-messenger systems and act synergistically at the somatotroph, which is the mechanistic basis for dual listings such as cjc-no dac / ipamorelin [23].

Is tesamorelin/ipamorelin dosage or sermorelin peptide dosage chart information provided here?

No. Strings such as tesamorelin/ipamorelin dosage, sermorelin peptide dosage chart and cjc-1295 with dac dosing protocol are recorded in the crosswalk as Declined. The compounds discussed are research reagents; this review reports mechanism and published literature only and gives no administration guidance.

11. Where to source for research

Research-grade sermorelin, Mod GRF 1-29, CJC-1295 (DAC), tesamorelin and ipamorelin are catalogued by several research-reagent suppliers, including Short Chain Aminos, BioPep, Catalyst Research and Apex Research Services. This is a statement of research availability only; no vendor has been assessed or endorsed. Researchers should request lot-specific certificates of analysis confirming sequence identity by mass spectrometry, RP-HPLC purity and, for CJC-1295, presence of the MPA linker, and should confirm that any material is labelled for laboratory research use.

Works Cited

1. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300:276-278. PMID: 6292724. DOI: 10.1038/300276a0.
2. Guillemin R, Brazeau P, Bohlen P, et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly / characterization of a 40-residue peptide. Biochem Biophys Res Commun. 1982. PMID: 7159418. DOI: 10.1016/0006-291x(82)91578-9.
3. Campbell RM, Lee Y, Rivier J, et al. GRF analogs and fragments: correlation between receptor binding, activity and structure. Peptides. 1991;12(3):569-574. PMID: 1656403. DOI: 10.1016/0196-9781(91)90103-v.
4. Gaudreau P, Boulanger L, Abribat T. Affinity of human growth hormone-releasing factor (1-29)NH2 analogues for GRF binding sites in rat adenopituitary. J Med Chem. 1992;35(10):1864-1869. PMID: 1534126. DOI: 10.1021/jm00088a023.
5. Frohman LA, Downs TR, Williams TC, et al. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-913. PMID: 3093533. DOI: 10.1172/JCI112679.
6. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. PMID: 2565342. DOI: 10.1172/JCI114049.
7. Boulanger L, Roughly P, Gaudreau P. Catabolism of rat growth hormone-releasing factor(1-29) amide in rat serum and liver. Peptides. 1992;13(4):681-689. PMID: 1437711. DOI: 10.1016/0196-9781(92)90173-z.
8. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID: 18031173. DOI: 10.2165/00063030-199912020-00007.
9. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. PMID: 18046908. DOI: 10.2147/ciia.2006.1.4.307.
10. Jette L, Leger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PMID: 15817669. DOI: 10.1210/en.2004-1286.
11. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. DOI: 10.1210/jc.2005-1536.
12. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 17018654. DOI: 10.1210/jc.2006-1702.
13. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. PMID: 16822960. DOI: 10.1152/ajpendo.00201.2006.
14. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19386527. DOI: 10.1016/j.ghir.2009.03.001.
15. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171-183. PMID: 18582981. DOI: 10.1016/j.jconrel.2008.05.010.
16. Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta. 2013;1830(12):5526-5534. PMID: 23639804. DOI: 10.1016/j.bbagen.2013.04.023.
17. Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. PMID: 17214611. DOI: 10.1111/j.1742-7843.2007.00008.x.
18. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338. DOI: 10.1056/NEJMoa072375.
19. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID: 20554713. DOI: 10.1210/jc.2010-0490.
20. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID: 25038357. DOI: 10.1001/jama.2014.8334.
21. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822. DOI: 10.1530/eje.0.1390552.
22. Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329. PMID: 9893708. DOI: 10.1007/s000180050257.
23. Muller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev. 1999;79(2):511-607. PMID: 10221989. DOI: 10.1152/physrev.1999.79.2.511.
24. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. PMID: 1333056. DOI: 10.1210/mend.6.10.1333056.
25. Gaylinn BD, Harrison JK, Zysk JR, et al. Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. Mol Endocrinol. 1993;7(1):77-84. PMID: 7680413. DOI: 10.1210/mend.7.1.7680413.
26. Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID: 32257855. DOI: 10.21037/tau.2019.11.30.
27. Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. PMID: 20143256. DOI: 10.1007/s11095-009-0045-6.

Research Use Only Disclaimer. This article is an academic literature review of peptide chemistry and pharmacology. The compounds described are strictly for research reference; not for human or veterinary use. No dosing, administration, therapeutic, diagnostic or health information is provided or implied, and the clinical trials cited are summarised solely as published literature.